Coherus BioSciences, Inc., a San Francisco, CA-based biologics platform company focused on biosimilars, closed a $55m Series C financing.
New investors KKR & Co. L.P., Venrock, RA Capital Management, Rock Springs Capital and Fidelity Biosciences joined existing investors Sofinnova Ventures, Lilly Ventures and Vivo Capital. In conjunction with the transaction, Ali Satvat, Director on KKR’s health care investing team, will join the Board of Directors of Coherus.
The company intends to use the funds to prosecute development plans, and optimize partnering strategies.
Led by Denny Lanfear, President and CEO, Coherus focuses on delivering high-quality biosimilar therapeutics to treat a range of chronic and often life-threatening diseases. The company leverages a strategic consortium of service providers aligned through ownership and shared incentives. Global commercialization partnerships include top-tier biopharma companies in Europe, Asia, and Latin America.